These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10602703)

  • 21. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
    Norman MH; Rigdon GC; Navas F; Cooper BR
    J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Batool F; Hasnat A; Haleem MA; Haleem DJ
    Acta Pharm; 2010 Jun; 60(2):129-40. PubMed ID: 21134850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2,2-Dicyanovinyl as a nonaromatic aryl bioisostere: synthesis, binding experiments and SAR studies of highly selective dopamine D4 receptor ligands.
    Haubmann C; Hübner H; Gmeiner P
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1969-72. PubMed ID: 10450964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Aug; 40(17):2688-93. PubMed ID: 9276014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.
    Martelle JL; Nader MA
    CNS Neurosci Ther; 2008; 14(3):248-62. PubMed ID: 18801115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor.
    Liégeois JF; Bruhwyler J; Damas J; Rogister F; Masereel B; Geczy J; Delarge J
    Eur J Pharmacol; 1995 Feb; 273(3):R1-3. PubMed ID: 7737323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5/6-ring Mannich bases.
    Linz S; Müller J; Hübner H; Gmeiner P; Troschütz R
    Bioorg Med Chem; 2009 Jul; 17(13):4448-58. PubMed ID: 19481941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs.
    Lidow MS; Goldman-Rakic PS
    J Pharmacol Exp Ther; 1997 Nov; 283(2):939-46. PubMed ID: 9353417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum.
    Ishikane T; Kusumi I; Matsubara R; Matsubara S; Koyama T
    Eur J Pharmacol; 1997 Feb; 321(2):163-9. PubMed ID: 9063684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine inhibits melatonin synthesis in photoreceptor cells through a D2-like receptor subtype in the rat retina: biochemical and histochemical evidence.
    Nguyen-Legros J; Chanut E; Versaux-Botteri C; Simon A; Trouvin JH
    J Neurochem; 1996 Dec; 67(6):2514-20. PubMed ID: 8931485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of dopamine D₄ receptor antagonists with planar chirality.
    Sanna F; Ortner B; Hübner H; Löber S; Tschammer N; Gmeiner P
    Bioorg Med Chem; 2013 Apr; 21(7):1680-4. PubMed ID: 23428965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.
    van Hes R; Smid P; Stroomer CN; Tipker K; Tulp MT; van der Heyden JA; McCreary AC; Hesselink MB; Kruse CG
    Bioorg Med Chem Lett; 2003 Feb; 13(3):405-8. PubMed ID: 12565939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and discovery of 3-piperazinyl-3,4-dihydro-2(1H)-quinolinone derivatives: a novel series of mixed dopamine D2/D4 receptor antagonists.
    Zhao H; Thurkauf A; Braun J; Brodbeck R; Kieltyka A
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2119-22. PubMed ID: 10999484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis.
    Hamamura T; Akiyama K; Akimoto K; Kashihara K; Okumura K; Ujike H; Otsuki S
    Brain Res; 1991 Apr; 546(1):40-6. PubMed ID: 1677305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.